Adenoviruses are currently used for delivering genes to cells, both in vitro and in vivo. There are several other methods for introducing foreign DNA into cells including the calcium phosphate precipitation and liposome fusion. Although widely applied to a variety of cell types with high efficiency, these techniques will, typically, deliver DNA to only 1-10% of neonatal cultured cardiac cells, whereas, the adult cells are completely resistant. In contrast, both neonatal and adult cardiac cells are highly sensitive to infection with adenoviruses. Indeed, Dr. Schneider's laboratory has shown approximately 100% efficiency of adenoviral mediated gene delivery to the latter cell type (7). Even though the neonatal cells are amenable to transfection by alternative methods, the applications for that are limited, considering the relatively low efficiency, as the effect of the transfected DNA is most readily evaluated only using a co-transfected reporter gene. In other words, it is difficult to test the effect of the delivered gene on any of the endogenous functions of the cell. Therefore, adenoviral technology is not only advantageous for gene delivery to the transfection-resistant adult cardiac cells but also to the neonatal. In addition, even in the case where a reporter gene is used, the number of cells necessary for the experiment will be considerably lessened by the usage of adenoviruses. Recently, we have successfully used adenoviral vectors to elucidate mechanisms involved in cardiac growth (1) and proliferation (6, 8). Other laboratories have also applied this methodology for better understanding of cardiac cell function. First generation adenoviruses, still currently in use for in vitro studies, are modified by a deletion in the early region 1 (E1) that renders them replication deficient, unless the fragment is provided in trans (4). Foreign DNA up to approximately 4.5 kb in length can be successfully integrated into the viral genome at the site of the deletion. The E1 region mainly controls expression of the late viral genes, but, in spite of its deletion, leaky expression from some of these genes has been detected. In consequence, there have been several attempts to further modify the adeno-vectors in that respect. Deletions of E2, or E4 regions, reduced but did not eliminate viral expression. In the latest generation of the adenoviral vectors, this problem has been eradicated by deletion of the virus's entire coding sequences (9, 10). This new vector, termed """"""""gutless"""""""", is not only of benefit for reducing the immunogenicity of adenoviruses in vivo, but also allows for an inset capacity up to approximately 34 kb. Although leaky expression of the viral genes may also be confounding in tissue culture experiments, the use of well- matched control viruses largely alleviate this problem. Accordingly, the adenovirus core facility will continue to generate the first generation adenoviral vector, in addition to the development of the """"""""gutless"""""""" vector, for which reagents have been kindly provided by Drs. M. Morsy and C.T. Caskey (Merck).

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL054313-06
Application #
6302328
Study Section
Project Start
2000-02-07
Project End
2001-01-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2000
Total Cost
$184,966
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Nassif, Michael E; LaRue, Shane J; Raymer, David S et al. (2016) Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circ Heart Fail 9:
Adamo, Luigi; Nassif, Michael; Tibrewala, Anjan et al. (2015) The Heartmate Risk Score predicts morbidity and mortality in unselected left ventricular assist device recipients and risk stratifies INTERMACS class 1 patients. JACC Heart Fail 3:283-90
Nassif, Michael E; Patel, Jayendrakumar S; Shuster, Jerrica E et al. (2015) Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail 3:146-53
Mann, Douglas L; Mochly-Rosen, Daria (2013) Translational medicine: mitigating risks for investigators. Nat Rev Drug Discov 12:327-8
Lombardi, Raffaella; Rodriguez, Gabriela; Chen, Suet Nee et al. (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119:1398-407
Lombardi, Raffaella; Bell, Achim; Senthil, Vinitha et al. (2008) Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res 79:109-17
Mann, Douglas L; Bozkurt, Biykem; Torre-Amione, Guillermo et al. (2008) Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci 1:142-5
Daw, E W; Lu, Y; Marian, A J et al. (2008) Identifying modifier loci in existing genome scan data. Ann Hum Genet 72:670-5
Marian, Ali J (2008) Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol 23:199-205
Daw, E Warwick; Chen, Suet Nee; Czernuszewicz, Grazyna et al. (2007) Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet 16:2463-71

Showing the most recent 10 out of 69 publications